A PHASE 1B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE ASCENDING DOSES OF KPL-716
- Registry ID
- KPL-716-C001
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- KINIKSA PHARMACEUTICALS, LTD.
- Start date
- 2018-10-10
- Completion date
- 2019-09-13
- Last update
- 2017-12-19
Conditions
- PRURITIS
- ATOPIC DERMATITIS
Related clinical trials
- A PHASE 2B, MULTICENTER, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMOTESKIMAB IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
- AN EXPLORATORY PROOF OF CONCEPT STUDY TO ASSESS THE PHARMACOKINETICS/PHARMACODYNAMICS OF NEMOLIZUMAB (CD14152) IN ADULT PARTICIPANTS WITH CHRONIC PRURITUS OF UNKNOWN ORIGIN (CPUO)
- A PHASE 2B, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF JNJ-95597528 FOR THE TREATMENT OF ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
- A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF GALVOKIMIG IN ADULT STUDY PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
- A MULTICENTER, RANDOMIZED, PARTICIPANT- AND INVESTIGATOR -BLINDED, PLACEBO-CONTROLLED, PHASE 2A STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF GIA632 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
- A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, DOSE-RANGING STUDY WITH AN OPEN-LABEL PERIOD INVESTIGATING THE EFFICACY AND SAFETY PROFILE OF KT-621 ADMINISTERED ORALLY TO PARTICIPANTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS.
View on source registry